Asthma Step Therapy on the NP Exam: GINA Tracks, Stepping Up and Stepping Down

Asthma step therapy on the FNP and AGNP exam comes down to two tracks, five steps, and one rule about when to move. GINA 2025 keeps Track 1, where low-dose ICS-formoterol is the reliever at every step and becomes maintenance and reliever therapy (MART) from step 3, as the preferred pathway for adults and adolescents, and Track 2, with a SABA or ICS-SABA reliever and daily ICS-based maintenance, as the alternative. The provider steps up when symptoms or risk are uncontrolled after technique, adherence and triggers have been checked, and steps down only after about three months of good control, never to SABA alone.

The pathway below follows the order an exam item expects: confirm the diagnosis, assess control and risk, place the patient on a step, then adjust.

Confirm the diagnosis before placing anyone on a step

GINA defines asthma by a history of variable respiratory symptoms (wheeze, shortness of breath, chest tightness, cough that vary over time and in intensity) plus confirmed variable expiratory airflow limitation. In adults the usual confirmation is spirometry showing a bronchodilator response: an increase in FEV1 of more than 12 percent and more than 200 mL from baseline 10 to 15 minutes after a SABA. Other acceptable evidence includes excessive diurnal variability in peak flow over two weeks, a significant FEV1 rise after four weeks of anti-inflammatory treatment, or a positive bronchial challenge test.

Document the objective evidence before the first controller prescription, because once a patient is on ICS the variability that proves the diagnosis may disappear.

Assess control and future risk, not just today's symptoms

GINA separates asthma control into two domains: symptom control over the past four weeks and risk of future adverse outcomes. Both drive the step decision.

None of the four features: well controlled. One or two: partly controlled. Three or four: uncontrolled. A validated questionnaire such as the Asthma Control Test can substitute.

Exacerbation risk factors are assessed separately and can justify a higher step even when symptoms look quiet. Key ones: any exacerbation in the past 12 months, ever intubated or in intensive care for asthma, high SABA use (three or more canisters a year raises exacerbation risk; twelve or more raises mortality risk), poor adherence or incorrect technique, FEV1 under 60 percent predicted, elevated blood eosinophils or FeNO despite ICS, smoking or vaping, obesity, chronic rhinosinusitis, food allergy, pregnancy, and socioeconomic barriers. A patient who answers "no" to all four symptom questions but had an emergency visit six months ago is not a step-down candidate.

The two tracks: what is prescribed at each step

The tracks differ in the reliever. In Track 1 it is low-dose ICS-formoterol; in Track 2 it is a SABA, or an ICS-SABA combination where available. GINA prefers Track 1 because the ICS-formoterol reliever strategy reduces severe exacerbations and oral corticosteroid courses compared with SABA-based regimens, and it removes the risk that a patient relies on SABA alone.

Other controllers (leukotriene receptor antagonist, allergen immunotherapy, early LAMA) are less effective, so an item asking for the "most appropriate" step expects the preferred choice.

Starting step. GINA suggests step 1 or 2 for symptoms less than four or five days a week with no night waking and no risk factors, step 3 for symptoms most days or night waking once a week or more, and step 4 for severely uncontrolled asthma or presentation with an acute exacerbation, sometimes with a short course of oral corticosteroids.

Track 1 dosing details

The as-needed and MART regimens use budesonide-formoterol (labeled in the United States as 160/4.5 mcg delivered dose per inhalation, which corresponds to the 200/6 mcg metered dose GINA quotes). As-needed use is one inhalation when symptoms occur. Low-dose MART is one inhalation once or twice daily plus one inhalation as needed; medium-dose MART is two inhalations twice daily plus as needed. The usual adult ceiling is 12 inhalations (72 mcg formoterol) in a single day; confirm the exact figure in the current GINA report and product labeling. ICS-LABA products containing salmeterol or vilanterol must never be used as relievers, because those LABAs are not rapid-onset.

In the United States, ICS-formoterol as a reliever remains off label. NAEPP 2020 nevertheless recommends it as single maintenance and reliever therapy (SMART) at steps 3 and 4 for patients aged 4 and older, and budesonide-albuterol, approved by the FDA in 2023, is the ICS-SABA reliever option GINA places in Track 2.

ICS dose categories you must be able to name

Step 3 versus step 4 is a dose question. GINA's table gives suggested total daily metered doses for adults and adolescents; it is not an equivalence table.

Fluticasone furoate has no separate medium dose. Confirm all figures, and any extrafine-particle rows, in the current GINA report before applying them to a specific product.

Stepping up: the checklist comes before the prescription

Uncontrolled symptoms or an exacerbation do not automatically mean the next step. GINA's sequence is: confirm the symptoms are from asthma, watch the patient use the inhaler and correct technique, assess adherence (missed doses, dispensing records), reduce modifiable risk factors (smoking, vaping, allergen exposure, nonselective beta-blockers, NSAIDs in sensitive patients), and treat comorbidities (rhinosinusitis, reflux, obesity, sleep apnea, anxiety and depression). Only then step up.

Three kinds of step-up exist:

• Sustained step-up for at least two to three months when the checklist is clean and control is still poor.
• Short-term step-up for one to two weeks during a viral infection or allergen exposure, done by the patient within a written action plan (in Track 1, more as-needed ICS-formoterol doses within the daily maximum).
• Day-to-day adjustment, which is built into Track 1 by design.

Every patient needs a written asthma action plan: daily treatment, how to recognize worsening, how to increase reliever and controller, when to start oral corticosteroids (typically prednisolone 40 to 50 mg daily, usually for 5 to 7 days in adults; confirm in the current report), and when to seek urgent care.

Stepping down: slow, documented and never to nothing

After about three months of good symptom control and stable lung function, consider stepping down to the lowest step that maintains control. Choose a time with no respiratory infection, travel or pregnancy, document the baseline, give a written action plan, and review within two to three months. Reduce the ICS dose gradually; GINA has long suggested reductions of about 25 to 50 percent at intervals of roughly three months (confirm in the current guideline). In Track 1, stepping down from MART means dropping the maintenance doses and continuing as-needed ICS-formoterol. In Track 2, stepping down from ICS-LABA means lowering the ICS dose, never stopping the ICS and keeping the LABA alone.

Complete withdrawal of ICS is not recommended for adults or adolescents. The floor is as-needed low-dose ICS-formoterol (Track 1) or ICS taken whenever SABA is taken (Track 2).

Monitoring and follow-up intervals

GINA recommends review one to three months after starting treatment and every three to twelve months afterwards, within one week of any exacerbation, and every four to six weeks in pregnancy. At every visit: symptom control, exacerbations since last visit, observed inhaler technique, adherence, side effects, lung function (spirometry at diagnosis, three to six months after starting treatment, then periodically, at least every one to two years in most adults), and the action plan.

Blood eosinophils and FeNO help confirm type 2 inflammation at steps 4 and 5 and guide biologic selection; they do not replace the symptom-control questions.

Referral triggers

Refer to a specialist when asthma remains uncontrolled or exacerbations continue despite medium- or high-dose ICS-LABA with good technique and adherence; when step 5 treatment or a biologic is being considered; when the diagnosis is uncertain or an alternative is suspected (inducible laryngeal obstruction, cardiac disease, COPD overlap); after a life-threatening exacerbation or intensive care admission; when the patient needs two or more oral corticosteroid courses a year; when occupational asthma is suspected; or when treatment side effects are a concern.

NAEPP 2020 versus GINA: what the exam may ask

An item written from either document gives the same answer at steps 3 and 4 (ICS-formoterol as both maintenance and reliever); the documents diverge at steps 1 and 2.

Patient education that the plan depends on

• Why the ICS matters even when the patient feels well, and why reliever-only use is dangerous.
• Observed inhaler technique at every visit, with a spacer for pMDIs.
• The written action plan, including the daily maximum for ICS-formoterol in Track 1.
• Trigger control: smoking and vaping cessation, allergen reduction where sensitized, annual influenza vaccination, and avoiding nonselective beta-blockers.
• When to seek care: reliever not lasting four hours, difficulty speaking in sentences, peak flow under 60 percent of personal best.

How the exam tests this

• The SABA-only distractor. Any option that leaves an adult with asthma on albuterol alone is wrong, including "reassure and continue as-needed albuterol."
• Step placement by dose. Items give a product and dose (fluticasone propionate 250 mcg twice daily is a medium daily dose of 500 mcg) and ask whether the patient is at step 3 or 4.
• Checklist before step-up. A clue about technique or adherence ("fills the controller every three months") means the answer is to fix that, not to add a drug.
• MART versus salmeterol. Fluticasone-salmeterol "as needed" is wrong because salmeterol is not rapid-onset.
• Step-down timing. Stepping down after four weeks, or stopping ICS and continuing LABA alone, is wrong.
• Risk overrides symptoms. No symptoms but an exacerbation in the past year means no step-down.
• Montelukast. The 2020 FDA boxed warning for neuropsychiatric events makes it a poor first choice when ICS options exist.

Practice question

A 34-year-old woman with asthma diagnosed by spirometry two years ago has been using budesonide-formoterol 160/4.5 mcg one inhalation as needed, as instructed. Over the past four weeks she reports symptoms three or four days a week, has woken with cough twice, and uses the inhaler four or five times a week, including one dose before running. She has not needed oral steroids or urgent care in the past year. She demonstrates correct inhaler technique, does not smoke, and has no new exposures. Spirometry today shows FEV1 84 percent of predicted. Which of the following is the most appropriate next step?

• A. Add montelukast 10 mg nightly and continue as-needed budesonide-formoterol.
• B. Prescribe budesonide-formoterol 160/4.5 mcg one inhalation twice daily as maintenance and continue one inhalation as needed for symptoms.
• C. Switch to fluticasone propionate-salmeterol 250/50 mcg one inhalation twice daily with albuterol as needed.
• D. Add tiotropium 2.5 mcg two inhalations daily.

Answer: B. She has three of four symptom-control features over four weeks (daytime symptoms more than twice a week, night waking, reliever use more than twice a week once the pre-exercise dose is excluded), so her asthma is uncontrolled on Track 1 step 2, and the step-up checklist is clean. The GINA step 3 Track 1 treatment is low-dose ICS-formoterol maintenance and reliever therapy, which is option B. Option A adds a less effective controller with a boxed warning instead of the preferred step. Option C moves her to a medium-dose Track 2 regimen, which skips step 3 and abandons the anti-inflammatory reliever. Option D is a step 5 add-on reserved for patients uncontrolled on medium- or high-dose ICS-LABA.

Key points

Related NPPace guides

• COPD in Primary Care: GOLD Groups, Inhaler Choice and When to Add What
• Outpatient Community-Acquired Pneumonia: Who Goes Home, Which Antibiotic and Follow-Up
• Sore Throat in the Clinic: Centor Scoring, When to Test for Strep and What to Prescribe
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?